Table 2.
Treatment administration of the combination of everolimus and capecitabine
| Evaluable patients (N = 31) | |
| No. of treatment cycles | |
| Median | 3 |
| Range | 1–15 |
| No. of treatment days with everolimus | |
| Mean ± SD | 104 ± 93 |
| Median | 76 |
| Range | 1–431 |
| Everolimus dose delivery | |
| No. of patients (%) | |
| Dose reduction due to toxicity | 5 (16) |
| Temporary treatment disruption due to toxicity | 6 (19) |
| Capecitabine dose delivery | |
| No. of patients (%) | |
| Dose reduction due to toxicity | 14 (45) |
| Temporary treatment disruption due to toxicity | 15 (48) |
SD standard deviation